🇺🇸 Pneumococcal 13-valent Conjugate Vaccine in United States

595 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Asthma — 78 reports (13.11%)
  2. Dyspnoea — 76 reports (12.77%)
  3. Chronic Obstructive Pulmonary Disease — 71 reports (11.93%)
  4. Hypertension — 68 reports (11.43%)
  5. Therapeutic Product Effect Incomplete — 64 reports (10.76%)
  6. Loss Of Personal Independence In Daily Activities — 60 reports (10.08%)
  7. Gastrooesophageal Reflux Disease — 46 reports (7.73%)
  8. Bronchiectasis — 44 reports (7.39%)
  9. Joint Injury — 44 reports (7.39%)
  10. Productive Cough — 44 reports (7.39%)

Source database →

Pneumococcal 13-valent Conjugate Vaccine in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Pneumococcal 13-valent Conjugate Vaccine approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Pneumococcal 13-valent Conjugate Vaccine in United States?

Emory University is the originator. The local marketing authorisation holder may differ — check the official source linked above.